XRP Eyes Breakout While Markets Remain Tense
The latest US inflation figures reignite tensions in the financial markets, and the crypto sector is not immune to this nervousness. Stuck below the $3 mark, XRP struggles to define a clear trend. In a climate where every economic data fuels speculation about the Fed’s monetary policy, Ripple’s asset moves in a zone of uncertainty. Between hopes for a breakout and risks of correction, pressure is mounting around a threshold that has become strategic.
In brief
- US inflation rises again and puts the Federal Reserve under pressure.
- The crypto market remains attentive, with XRP stuck around the critical $3 threshold.
- Fed rate cut expectations have slightly receded after the release of the CPI.
- Technical indicators signal a potential breakout, with a key resistance at $3.35.
US inflation reignites tensions: Fed under pressure, XRP on hold
The monthly report from the Bureau of Labor Statistics, published this Thursday, September 11, surprised the markets. The Consumer Price Index (CPI) rose 0.4 % in August (compared to 0.2 % in July), bringing annual inflation to 2.9 %, its highest level since January, while the crypto market is recovering .
The “core” version of the index, which excludes food and energy, remained stable at +3.1 % year-over-year. This data, deemed critical, tempered hopes for a rapid easing of US monetary policy. Expectations for a 0.25 point rate cut by the Fed in September fell from 91 % to 88.7 %”, according to CME Group’s FedWatch tool.
In this tense context, risk assets, including XRP, react cautiously. Ripple’s crypto clings to the psychological threshold of $3.00, failing to establish a clear direction. This status quo is notably explained by a hesitant market dynamic, characterized by “an aggressive push and pull between buyers and sellers”. Specifically, here are the key points :
- The overall CPI stands at 2.9 %, compared to 2.7 % the previous month ;
- The Core CPI remains at 3.1 %, a level closely watched by the Fed ;
- The probability of a rate cut at the next FOMC meeting has slightly decreased ;
- XRP is stuck around $3.00, without a breakout up or down.
In summary, macroeconomic data has slowed speculative momentum around XRP, without reversing the trend. The crypto market, like stock indices, is now in a wait-and-see phase, suspended to the next monetary policy announcement.
The rise of derivatives
While the macroeconomic context weighs on the short-term prospects of the entire crypto market, Ripple’s crypto shows specific signs of resilience. Open Interest in XRP futures contracts reached $8.15 billion this Thursday, compared to $7.37 billion last Sunday.
This significant increase in speculative engagement reflects a renewed investor interest in the asset and can be interpreted as anticipation of a significant directional move. At this stage, the $3.00 threshold acts as a technical pivot. Investors are buying dips towards $2.91, a level corresponding to the 50-day exponential moving average (EMA 50).
From a technical analysis perspective, signals point upward. The MACD configuration, in “buy signal” mode since Monday, and a stable RSI at 54 indicate a moderate but real bullish momentum.
The RSI increase, approaching an overbought zone, confirms sustained buying pressure. Furthermore, the next critical zone identified by analysts is $3.35, last tested in mid-August. If this resistance were to break, the market could then target the peak reached last July 18 at $3.65 .
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.

Australian Dollar crumbles as job losses shatter RBA rate hike hopes

Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.

